Medtronic files PMA application for Talent graft:
This article was originally published in Clinica
Medtronic has filed the final module of a US PMA application for its Talent abdominal stent graft system. The Talent graft is a minimally-invasive device for the treatment of abdominal aortic aneurysm (AAA), designed to offer broad patient applicability and ease of use. The Minneapolis, Minnesota-based company said that the device would complement its AneuRx AAAdvantage stent graft. The submission contained data from a clinical trial in which patients revceiving the Talent graft experienced lower rates of death, myocardial infarction, respiratory failure, paraplegia, and blood loss, compared with subjects treated with open surgery, at 12 months.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.